Drug Approval | June 01, 2023
Lupin receives USFDA approval from Obeticholic Acid Tablets
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
For the treatment of Superficial Femoral Artery
The product is expected to be launched in June 2023
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
